Trial Profile
Phase II Trial of CT-2103 (Xyotax) With Capecitabine as First-Line Chemotherapy for Patients With Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Paclitaxel poliglumex (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 18 Jun 2012 Actual end date (1 Jan 2009) added as reported by ClinicalTrials.gov.
- 18 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2008 Primary endpoint not met. Results presented at the American Society of Clinical Oncology (ASCO) 2008.